Slater A D, Klein J B, Gray L A
Am J Surg. 1987 Jun;153(6):582-93. doi: 10.1016/0002-9610(87)90167-x.
The results of orthotopic cardiac transplantation have improved dramatically since the early experiences in the late 1960s. After almost 20 years of research and experience and the introduction of cyclosporine, 1 and 5 year survival rates are now 80 percent and 60 percent, respectively. The number of potential recipients far exceeds that of available donors, which is the limiting factor in cardiac transplantation. Complications related to immunosuppressive therapy remain significant, and despite decreased length of hospitalization, costs remain high. The majority of patients have good functional rehabilitation and are free of cardiac symptoms. Moreover, orthotopic cardiac transplantation has finally become a therapeutic treatment of end-stage heart disease.
自20世纪60年代末的早期经验以来,原位心脏移植的结果有了显著改善。经过近20年的研究和经验积累以及环孢素的引入,现在1年和5年生存率分别为80%和60%。潜在受者的数量远远超过可用供者的数量,这是心脏移植的限制因素。与免疫抑制治疗相关的并发症仍然很严重,尽管住院时间缩短了,但成本仍然很高。大多数患者功能康复良好,没有心脏症状。此外,原位心脏移植最终已成为终末期心脏病的一种治疗方法。